-
Mashup Score: 154An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations - 1 month(s) ago
ML2006a4 has improved affinity for SARS-CoV-2 Mpro and reduced sensitivity to mutations conferring resistance to nirmatrelvir or ensitrelvir.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 152An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations - 1 month(s) ago
ML2006a4 has improved affinity for SARS-CoV-2 Mpro and reduced sensitivity to mutations conferring resistance to nirmatrelvir or ensitrelvir.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
An antiviral for #SARSCoV2 based on the hepatitis C drug boceprevir matches the performance of approved drugs like #nirmatrelvir, offering a new tool for #COVID19 arsenals. @ScienceTM https://t.co/lxwxdKLhxy https://t.co/19ChN25O8h